Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Atezolizumab + Cabozantinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Atezolizumab||Tecentriq||RG7446|MPDL3280A||Immune Checkpoint Inhibitor 141 PD-L1/PD-1 antibody 83||Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in PD-L1 positive advanced or metastatic urothelial carcinoma not eligible for cisplatin-containing chemotherapy, in advanced or metastatic urothelial carcinoma not eligible for chemotherapy or progressed on platinum-based chemotherapy, in metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, as first-line therapy in metastatic NSCLC with high PD-L1 expression (TC>=50% or IC>=10%) and without EGFR or ALK alterations, for adjuvant treatment in patients with PD-L1-positive (>=1% tumor cell expression) NSCLC, in combination with bevacizumab, paclitaxel, and carboplatin as first-line therapy for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound and carboplatin in metastatic non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound in advanced or metastatic triple-negative breast cancer expressing PD-L1, in combination with carboplatin and etoposide in extensive-stage small cell lung cancer, in combination with bevacizumab in hepatocellular carcinoma without prior systemic therapy, and in combination with cobimetinib and vemurafenib in BRAF V600-mutated melanoma (FDA.gov).|
|Cabozantinib||Cometriq||Cabometyx|Cabozantinib-s-malate|XL184||AXL Inhibitor 27 FLT3 Inhibitor 57 KIT Inhibitor 52 MET Inhibitor 53 RET Inhibitor 43 ROS1 Inhibitor 17 VEGFR2 Inhibitor 35||Cometriq (Cabometyx, cabozantinib) inhibits several receptor tyrosine kinases, including VEGFR2, FLT3, AXL, MET, RET, ROS1 fusions, and c-KIT (PMID: 27370605, PMID: 21926191). Cometriq (cabozantinib) is FDA approved for use in patients with medullary thyroid cancer, Cabometyx (cabozantinib) is FDA approved for use in patients with advanced renal cell carcinoma, hepatocellular carcinoma previously treated with sorafenib, adult and pediatric patients 12 years and older with locally advanced or metastatic differentiated thyroid cancer, and in combination with Opdivo (nivolumab) in patients with advanced renal cell carcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03170960||Phase Ib/II||Atezolizumab + Cabozantinib||Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors||Active, not recruiting||USA | ITA | FRA | ESP | DEU | BEL||3|
|NCT04400474||Phase II||Atezolizumab + Cabozantinib||Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN)||Recruiting||ESP||0|
|NCT05168163||Phase II||Atezolizumab + Cabozantinib Cabozantinib Atezolizumab + Lenvatinib Lenvatinib||Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer||Not yet recruiting||USA||0|
|NCT04338269||Phase III||Cabozantinib Atezolizumab + Cabozantinib||A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment (CONTACT-03)||Active, not recruiting||USA | ITA | FRA | ESP | DEU | CAN||9|
|NCT05019703||Phase II||Atezolizumab + Cabozantinib||Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study||Not yet recruiting||USA||0|
|NCT05039281||Phase Ib/II||Atezolizumab + Cabozantinib||Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma||Not yet recruiting||USA||0|
|NCT04446117||Phase III||Enzalutamide Atezolizumab + Cabozantinib Abiraterone + Prednisone||Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)||Recruiting||USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT||19|
|NCT05168618||Phase II||Atezolizumab + Cabozantinib||Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial||Recruiting||USA||0|
|NCT03264066||Phase II||Atezolizumab + Cabozantinib||A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors||Completed||USA | DEU | BEL||3|
|NCT04289779||Phase II||Atezolizumab + Cabozantinib||Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer (ABATE) (ABATE)||Recruiting||USA||0|
|NCT04471428||Phase III||Docetaxel Atezolizumab + Cabozantinib||Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy (CONTACT-01)||Active, not recruiting||USA | ITA | FRA | ESP | DEU | BEL | AUT||8|
|NCT03755791||Phase III||Cabozantinib Sorafenib Atezolizumab + Cabozantinib||Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312)||Recruiting||USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT||26|
|NCT04820179||Phase II||Atezolizumab + Cabozantinib||Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer||Recruiting||USA||0|